Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice.

Psoriasis is a chronic inflammatory skin disorder that is triggered by immune-mediated, genetic, and environmental factors. Moxifloxacin is a fluoroquinolone antibiotic with extended non-expected anti-inflammatory and immune-modulating effects. This study aims to investigate the possible influence of two different concentrations of moxifloxacin emulgel on psoriasis induced via imiquimod in mice. Dividing 48 mice into six groups (8 mice for each group), all groups gated imiquimod to induce psoriasis (except group I) for 7 days. The induction group (Group II) received imiquimod cream for 7 days. The vehicle group obtained emulgel base for 7 days. The rest of the groups got calcipotriol 0.005% ointment, moxifloxacin 3% emulgel, and moxifloxacin 5% emulgel, respectively, once daily for a further 7 days after the induction period. Topical moxifloxacin had important anti-psoriatic activity by diminishing the Psoriasis Area Severity Index (PASI) scores and improving histological alterations during imiquimod application. Moreover, moxifloxacin significantly lowered the levels of inflammatory biomarkers like TGF-β, TNF-α, IL-17, IL-1β, IL-23, and VEFG while increasing levels of anti-inflammatory biomarkers IL-10 and IL-37. Moxifloxacin also suppressed oxidative indicators such as MDA and elevated antioxidant enzyme levels, such as catalase. Moxifloxacin has substantial anti-psoriatic action against imiquimod-induced psoriasis through its anti-proliferative and anti-inflammatory effects. Furthermore, moxifloxacin has a restorative effect on the histopathological alterations of mice's skin induced by imiquimod.